One of the ways that the COVID-19 pandemic had a profound impact on the pharma industry was how it highlighted the importance of pharmacovigilance. As personalized medicine gained traction, drug developers had to evolve their strategies to ensure safety and efficacy. In their report, “The Future of Pharmacovigilance,” Dr. Sabine Jeck-Thole and Ben Enejo, partners…
Why growth for pharmaceutical companies can be dangerous
Prosperity can be a double-edged sword for pharma companies. While there are obvious financial advantages to selling more drugs, growth phases often lead to an uptick in quality problems, said Craig Wylie, managing partner USA at Arthur D. Little. A solid plan is needed to help pharma companies keep track of their processes as they…